Thursday, March 21, 2013
A Yale University
group has designed a nanoparticle that selectively delivered an
immunosuppressant to immune cells and improved survival in mouse models of
lupus.1 The nanoparticle delivery platform has been exclusively
licensed to Immunova LLC,
which is selecting an anti-inflammatory compound to take into the clinic.
L. SciBX 6(11);
doi:10.1038/scibx.2013.256 Published online March 21, 2013
1. Look, M. et al. J.
Clin. Invest.; published online March 1, 2013; doi:10.1172/JCI65907 Contact:
Tarek M. Fahmy, Yale University, New Haven, Conn. e-mail: firstname.lastname@example.org
2. Scindia, Y. et al.
Arthritis Rheum. 58, 3884-3891 (2008)
AND INSTITUTIONS MENTIONED
Immunova LLC, New Haven, Conn.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
University of Virginia, Charlottesville, Va.
University of Washington, Seattle, Wash.
Yale University, New Haven, Conn.